Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29713160 | 1.00 | KMT2A (0.47) | KMT2AMEN1ALDH1A1LMNACES2 | |
| SCHEMBL11276948 | 0.87 | KMT2A (0.50) | KMT2AMEN1ALDH1A1LMNACES2 | |
| SCHEMBL10683568 | 0.83 | NR3C2 (0.39) | KMT2AMEN1ALDH1A1LMNAGAA | |
| SCHEMBL10650360 | 0.83 | PIN1 (0.42) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL1274762 | 0.81 | ALDH1A1 (0.56) | KMT2AMEN1ALDH1A1LMNACES2 | |
| SCHEMBL30059683 | 0.81 | ALDH1A1 (0.56) | KMT2AMEN1ALDH1A1LMNACES2 | |
| SCHEMBL22980154 | 0.80 | KMT2A (0.44) | KMT2AALDH1A1LMNA | |
| SCHEMBL9984510 | 0.80 | KMT2A (0.46) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL8676087 | 0.80 | KMT2A (0.50) | KMT2AMEN1ALDH1A1LMNACES2 | |
| SCHEMBL8410789 | 0.80 | CES2 (0.56) | KMT2AMEN1ALDH1A1LMNACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432953-B1 | — | — | None | — | — | US | disclosed |
| EP-4694889-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES | Acelot, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024216203-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES | ACELOT, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2023-12-07 | — | — | US | disclosed |
| EP-4259613-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2023-10-18 | — | — | EP | disclosed |
| CN-116761796-A | Aryl derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2023-09-15 | — | — | CN | disclosed |
| CN-115160340-B | Small molecular compound with ACK1 inhibition activity and application thereof | 四川大学华西医院 | 2023-07-21 | — | — | CN | disclosed |
| WO-2022112345-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | disclosed |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-09-30 | — | — | US | disclosed |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-09-30 | — | — | US | disclosed |
| WO-1997002824-A1 | USE OF A TACHYKININ ANTAGONIST AND A MUSCARINIC ANTAGONIST AND/OR AN ANTIHISTAMINE TO TREAT MOTION SICKNESS | MERCK SHARP & DOHME LIMITED (GB) | 1997-01-30 | — | — | WO | disclosed |
| EP-0748320-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1996029328-A1 | MORPHOLINE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-09-26 | — | — | WO | disclosed |
| WO-1996020009-A1 | USE OF A TACHYKININ ANTAGONIST AND AN OPIOID ANALGESIC | MERCK SHARP & DOHME LIMITED (GB) | 1996-07-04 | — | — | WO | disclosed |
| WO-1996007649-A1 | MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-03-14 | — | — | WO | disclosed |
| WO-1995023798-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995016679-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-06-22 | — | — | WO | disclosed |
| EP-0424021-B1 | Antimuscarinic bronchodilators | PFIZER LTD (GB) | 1994-03-02 | — | — | EP | disclosed |
| US-5171744-A | Antimuscarinic bronchodilators | PFIZER INC. (US) | 1992-12-15 | — | — | US | disclosed |
| EP-0424021-A1 | Antimuscarinic bronchodilators | Pfizer Limited (GB) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391739-A1 | ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPV3, TRPM6, TRPM4 | KMT2A 2278/4885MEN1 1929/4885ALDH1A1 1232/4885 |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA2B | KMT2A 2009/4885MEN1 2960/4885ALDH1A1 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.